MicroRNA-141 Is a Biomarker for Progression of Squamous Cell Carcinoma and Adenocarcinoma of the Lung: Clinical Analysis of 125 Patients

Abstract

Lung cancer is the most common malignant tumor worldwide. MicroRNA has become an ideal biomarker for cancer diagnosis, prognosis and therapy. The relationship between microRNA-141 and non-small cell lung cancer (NSCLC) is contradictory. Thus, in current study, we aimed to investigate the level of microRNA-141 in NSCLC tissues and to evaluate its potential clinical value. This study enrolled 125 NSCLC patients (75 males and 50 females) with a median age of 61 years (range, 23-90 years). NSCLC patients included 23 squamous cell carcinomas (SCCs), 101 adenocarcinomas (ADCs) and 1 large cell carcinoma. The expression level of microRNA-141 was significantly higher in NSCLC tissues than in adjacent lung tissues (P < 0.001), detected by real time RT-PCR. Receiver operating characteristic (ROC) exhibited a moderate diagnostic value of microRNA-141 for NSCLC with the area under curve of 0.707. The microRNA-141 expression increased with the larger tumor size (P = 0.002), lymph node metastasis (P = 0.018) and advanced stage (P = 0.022) in NSCLC patients. For subgroup analysis, microRNA-141 expression in SCC was correlated with tumor size (r = 0.490, P = 0.018), and in ADC, microRNA-141 level was positively associated with tumor size (r = 0.222, P = 0.026), lymph node metastasis (r = 0.242, P = 0.015) and TNM stage (r = 0.210, P = 0.035). Furthermore, univariate analysis revealed that the expression of microRNA-141 was an independent prognostic indicator of ADC. In conclusion, microRNA-141 is a potential biomarker for the molecular diagnosis and risk stratification of NSCLC.

Diagnostic MicroRNA Biomarker Discovery for Non-Small-Cell Lung Cancer Adenocarcinoma by Integrative Bioinformatics Analysis

“…This miRNA was a powerful indicator for predicting the chemosensitivity of lung adenocarcinoma patients to docetaxel-based chemotherapy regimen. Zhang et al [32] analyzed the clinical potential of miR-141 and found that this miRNAs was positively correlated with the tumor size, lymph NOGe metastasis, and TNM stage of lung adenocarcinomas. Meanwhile, Liu et al [34] screened that the upregulation of plasma exosomal miRNAs miR-23b-3p, miR-10b-5p and miR-21-5p was strongly connected with the poor overall survival of lung adenocarcinoma patients.…”

The Roles of MicroRNA-141 in Human Cancers: From Diagnosis to Treatment

“…MiR-141 can also be a potential biomarker for the molecular diagnosis and risk stratification in NSCLC. MiR-141 was reported to be upregulated in NSCLC tissues compared with the corresponding normal ones by several independent studies [62,84,144]. This excessive expression of miR-141 was further proved to be associated with the larger tumor size, lymph node metastasis and advanced stage in NSCLC patients.…”

Expression of selected miRNA, RARβ and FHIT genes in BALf of squamous cell lung cancer (squamous-cell carcinoma, SCC) patients: a pilot study

“…Previous studies have also identified overexpression of miRNA-141 and miRNA-217 in tumor tissue [8]. Interestingly, upregulation of miRNA-217 was associated with an advanced status of NSCLC.…”

“…miRNA-34a regulates tumor cell apoptosis, and one very promising approach in NSCLC therapy involves the restoration of its correct function [7]. miRNA-141 is known as a predictive marker in NSCLC as it regulates sensitivity to cisplatin [8]. Apart from its prognostic value, miRNA-141 overexpression correlates with the more advanced stage of NSCLC and has potential as a diagnostic molecular biomarker.…”